Eporise 5000 IU (IV/SC Injection)
5000 IU pre-filled syringe: ৳ 2,100.00
Medicine Details
| Category | Details |
|---|---|
| Generic | Erythropoietin alfa |
| Company | Ziska pharmaceuticals ltd |
| Also available as |
Product Title
- Eporise Recombinant Human Erythropoietin (EPO)
Product Category
- Medicine
- Healthcare
- Pharmaceuticals
- Anemia Treatment
Description
- Recombinant human erythropoietin expressed in Chinese hamster ovary cells
- 165 amino acid sequence identical to human urinary EPO
- Apparent molecular weight of 30,400 daltons
Indications
- Treatment of anemia in chronic kidney disease (CKD) patients on dialysis and not on dialysis
- Treatment of anemia due to Zidovudine in HIV-infected patients
- Treatment of anemia due to concomitant myelosuppressive chemotherapy
- Reduction of allogeneic RBC transfusions in patients undergoing elective, noncardiac, nonvascular surgery
- Prevention of anemia of prematurity in infants with a birth weight of 750 to 1500 gm and gestational age of less than 34 weeks
Dosage Instructions
- Evaluate iron status and nutritional factors before and during treatment
- Monitor hemoglobin levels at least weekly until stable
- Consider initiating treatment based on hemoglobin level and other clinical considerations
- Dose adjustments based on hemoglobin response and RBC transfusion needs
- Starting doses for different patient groups and conditions
- Different dosing recommendations for zidovudine-treated HIV-infected patients and cancer chemotherapy patients
- Dosage adjustments for hemoglobin levels exceeding certain thresholds
Administration Instructions
- Preparation and administration guidelines including avoiding shaking or freezing the product, protecting from light, visual inspection prior to administration, and discarding unused portions
Interaction
- Possible potentiation of Eporise effect by simultaneous administration of haematinic agents such as ferrous sulphate in cases of deficiency
Contraindications
- Uncontrolled hypertension
- Serious allergic reactions to Erythropoietin alfa
- Patients who develop Pure Red Cell Aplasia (PRCA) following treatment with any erythropoietin
Side Effects
- Adverse reactions reported in Eporise treated patients including hypertension, arthralgia, muscle spasm, pyrexia, dizziness, medical device malfunction, vascular occlusion, upper respiratory tract infection, cough, rash, injection site irritation, nausea, vomiting, myalgia, stomatitis, weight decrease, leukopenia, bone pain, hyperglycemia, headache, depression, dysphagia, hypokalemia, thrombosis, and fall in serum ferritin values in premature infants
Pregnancy & Lactation
- No adequate and well-controlled studies in pregnant women
- Reproduction toxicology observed in animal studies
- Caution advised for pregnant and lactating surgical patients participating in an autologous blood predonation programme
- Caution advised in nursing women with consideration of breast-feeding benefits and Erythropoietin alfa therapy benefits
Overdose Effects
- Eporise overdosage management with discontinuation or reduction of dosage and/or with phlebotomy
- Observation of severe hypertension following overdose with ESAs
Therapeutic Class
- Drugs for Haemolytic Hypoplastic & Renal Anemia
Storage Conditions
- Store at 2°C to 8°C
- Do not freeze or shake
- Store in original package to protect from light